Skip to main content
. Author manuscript; available in PMC: 2014 Sep 19.
Published in final edited form as: Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654. doi: 10.1002/14651858.CD006654.pub2

Table 1. Suggested design of future study.

Methods Allocation: randomised - clearly described generation of sequence and concealment of allocation.
Blindness: double - described and tested.
Duration: 6 months minimum.
Participants Diagnosis: schizophrenia (operational criteria).
N=2700.*
Age: any.
Sex: both.
History: any.
Interventions

  1. Olanzapine: dose ~ 10-20 mg/day. N=300.

  2. Amisulpride: dose ~ 400-800 mg/day. N=300.

  3. Aripiprazole: dose ~ 10-30 mg/day. N=300.

  4. Clozapine: dose ~ 300-800 mg/day. N=300.

  5. Quetiapine: dose ~300-800 mg/day. N=300.

  6. Risperidone: dose ~ 4-8 mg/day. N=300.

  7. Sertindole: dose ~ 12-24 mg/day. N=300.

  8. Ziprasidone: dose ~ 120-160 mg/day. N=300.

  9. Zotepine: dose ~ 100-300 mg/day. N=300.
Outcomes Leaving study early (any reason, adverse events, inefficacy).
Service outcomes: hospitalised, time in hospital, attending out patient clinics.
Global impression: CGI**, relapse.
Mental state: PANSS.
Adverse events: UKU.
Employment, family satisfaction, patient satisfaction.
*

power calculation suggested 300/group would allow good chance of showing a 10% difference between groups for primary outcome.

**

Primary outcome